8th Translational Research Conference
Lymphoid Malignancies
October 2-4, 2025 – Estoril, Portugal
Chairs: Michael Hallek, Georg Lenz, Laurie Sehn, Louis Staudt, Catherine Wu

Thursday, October 2nd, 2025

08:30–08:35 Welcome

SESSION I – Biology of lymphoma
Chairs: Jennifer G. Abelin (Cambridge, MA), Louis Staudt (Bethesda)

08:35-08:40	Introduction	Jennifer G. Abelin (Cambridge, MA) Louis Staudt (Bethesda)
08:40-09:00	Epigenetic changes in lymphoma	Ari Melnick (Barcelona)
09:00-09:20	What do we learn from proteomics for the biology of lymphoma	Thomas Oellerich (Frankfurt)
09:20-09:40	Immunopeptidomics of lymphoma	Jennifer G. Abelin (Cambridge, MA)
09:40-09:47	*Selected brief oral communication* *The SOX11: SMARCA4 complex drives oncogenic transcriptional programs in mantle cell lymphoma*	*Anna de Bolòs (Barcelona)*
09:47- 09:50	*Discussion*	
09:50-10:20	*Panel discussion*	
10:20-10:40	***Coffee Break***	

SESSION II – Biology of lymphoma
Chairs: Ari Melnick (Barcelona), Teresa Palomero (New York)

10:40-10:45	Introduction	Ari Melnick (Barcelona) Teresa Palomero (New York)
10:45-11:05	Mantle cell lymphoma, the basic biology and genomics	Elias Campo (Barcelona)
11:05-11:25	Functional genomics of diffuse large B cell lymphoma	Louis Staudt (Bethesda)
11:25-11:45	Somatic genetics of diffuse large B cell lymphoma	Riccardo Dalla-Favera (New York)
11:45-12:05	T-cell lymphoma	Teresa Palomero (New York)

12:05-12:12	*Selected brief oral communication* *Investigating the Role of RhoA and its Mutations in Diffuse Large B-Cell Lymphoma*	*Ariana Jacobs (Frankfurt)*
12:12-12:15	*Discussion*	
12:15-12:45	*Panel discussion*	

12:45-14:20 ***Lunch***

SESSION III – Clonal evolution
Chairs: Ryan Morin (Burnaby), Catherine Wu (Boston)

14:20-14:25	Introduction	Ryan Morin (Burnaby) Catherine Wu (Boston)
14:25-14:45	Genetic changes - Chronic lymphocytic leukemia	Catherine Wu (Boston)
14:45-15:05	Epigenomic characterization of lymphoid neoplasms	José Ignacio Martín-Subero (Barcelona)
15:05-15:25	The evolution of molecular taxonomies for B-cell lymphomas	Ryan Morin (Burnaby)
15:25-15:32	*Selected brief oral communication* *Deciphering the function of every lymphoma hotspot mutation using primary human germinal centre B cells*	*Galina Shevchenko (Cambridge)*
15:32-15:35	*Discussion*	
15:35-16:05	*Panel discussion*	

16:05-16:30 ***Coffee break***

SESSION IV – Lymphoma cell interactions in the tumor microenvironment
Chairs: Michael Hallek (Cologne), Martina Seiffert (Heidelberg)

16:30-16:35	Introduction	Michael Hallek (Cologne) Martina Seiffert (Heidelberg)
16:35-16:55	Microenvironment of lymphoid malignancies	Martina Seiffert (Heidelberg)
16:55-17:15	The landscape of tumor cell states and ecosystems in lymphoma	Ash Alizadeh (Stanford)
17:15-17:35	Dynamics of follicular lymphoma in the context of the microenvironment	Sandrine Roulland (Marseille)
17:35-17:55	Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients	Parry Erin (Boston)
17:55-18:15	Siglec-6 as a therapeutic target for cell migration and adhesion in chronic lymphocytic leukemia	Natarajan Muthusamy (Columbus)

18:15-18:22	*Selected brief oral communication* *The spatial organization of MYC-BCL2 co-expressing cells relates to T-cell exhaustion and survival in Diffuse Large B-Cell Lymphoma*	*Anand Jeyasekharan (singapore)*
18:22- 18:25	*Discussion*	
18:25-18:45	*Panel discussion*	
18:45-20:00	**Mentored Poster Walks and Welcome Get Together** Biology Poster Leaders: Michael Green (Houston), Ryan Morin (Burnaby) Clinical Poster leaders: Michael Hallek (Cologne), Catherine Thieblemont (Paris)	

Friday, October 3rd, 2025

09:00-10:00	**3 Simultaneous Meet the Expert sessions (non-clinical)**	
	1, Epigenetics and Lymphoma	Ari Melnick (Barcelona)
	2, T-cell lymphoma	Teresa Palomero (New York)
	3, Pathology and pathogenesis of lymphoid malignancies	Elias Campo (Barcelona)
10:00-10:20	***Coffee break***	

SESSION V – Monoclonal antibodies & non-cellular immune therapies
Chairs: Toby A. Eyre (Oxford), Laurie Sehn (Vancouver)

10:20-10:25	Introduction	Toby A. Eyre (Oxford) Laurie Sehn (Vancouver)
10:25-10:45	Bispecific antibodies in lymphoma - state of the art	Laurie Sehn (Vancouver)
10:45-11:05	Bispecific antibodies - alone or in combination, sequencing with CART cells, antigen loss and other considerations	Martin Hutchings (Copenhagen)
11:05-11:25	Trispecific and other novel antibodies in development	Catherine Thieblemont (Paris)
11:25-11:32	*Selected brief oral communication* *Glofitamab+R-CHOP in patients with previously untreated large B-cell lymphoma defined as high risk by circulating tumor DNA (ctDNA) dynamics: primary results*	*Martin Hutchings (Copenhagen)*
11:32- 11:35	*Discussion*	
11:35-12:05	*Panel discussion*	
12:05-13:40	***Lunch***	

SESSION VI – Cellular immune therapies
Chairs: Veronika Bachanova (Minneapolis), Martin Hutchings (Copenhagen)

13:40-13:45	Introduction	Veronika Bachanova (Minneapolis) Martin Hutchings (Copenhagen)
13:45-14:05	Mechanisms of resistance to chimeric antigen receptor-T cells	Michael Green (Houston)
14:05-14:25	New autologous CART beyond CD19 CART including CD22 CART	Matthew J Frank (Stanford)

14:25-14:45	NK cell based therapies in lymphoid malignancies	Veronika Bachanova (Minneapolis)
14:45-14:52	*Selected brief oral communication* *Next-generation CAR T-cells: dual antigen targeting and cytolytic enhancement for tackling immune escape mechanisms in leukemia and lymphoma*	*Anthea Wirges (Berlin)*
14:52-14:55	*Discussion*	
14:55-15:25	*Panel discussion*	
15:25-15:55	***Coffee break***	

SESSION VII – Small molecular pathway inhibitors
Chairs: Georg Lenz (Münster), Jared Johnson (Boston)

15:55-16:00	Introduction	Georg Lenz (Münster) Jared Johnson (Boston)
16:00-16:20	An atlas of substrate specificities for the human serine/. threonine kinome	Jared Johnson (Boston)
16:20-16:40	The role of non-covalent BTK inhibitors such as pirtobrutinib and. BTK degraders in lymphoma therapy	Toby A. Eyre (Oxford)
16:40-17:00	Rewiring cancer drivers to activate apoptosis	Sai Gourisankar (Stanford)
17:00-17:07	*Selected brief oral communication* *Impact of treatment with ibrutinib or venetoclax on CAR-T cell generation in patients with chronic lymphocytic leukemia. Interim analysis of the GIMEMA CLL2020 study*	*Rebecca Jones (Torino)*
17:07- 17:10	*Discussion*	
17:10-17:40	*Panel discussion*	

Saturday, October 4th, 2025

07:30-08:30	**3 Simultaneous Meet the Expert Sessions (Clinical)**	
	1, Regulation of apoptosis	Nathalie Javidi-Sharifi (Boston)
	2, Treatment of diffuse large B-cell lymphoma	Laurie Sehn (Vancouver)
	3, Genetics and genomics of CLL	Catherine Wu (Boston)

SESSION VIII – Development of novel treatment paradigms
Chairs: Nathalie Javidi-Sharifi (Boston), Michael Hallek (Cologne)

08:35-08:40	Introduction	Nathalie Javidi-Sharifi (Boston) Michael Hallek (Cologne)
08:40-09:00	Targeting the tumor microenvironment in relapsed/refractory CLL	Michael Hallek (Cologne)
09:00-09:07	*Selected brief oral communication* *NF-kB rewiring by the tumour microenvironment drives BH3-mimetic resistance in DLBCL*	*Aimilia Vareli (Brighton)*

09:07-09:10 *Discussion*

09:10-09:30 *Panel discussion*

09:30-09:40 ***Coffee break***

SESSION IX – Novel Bio markers for diagnostic and therapeutic monitoring
Chairs: Michael Hallek (Cologne), Catherine Thieblemont (Paris)

09:40-09:45	Introduction	Michael Hallek (Cologne) Catherine Thieblemont (Paris)
09:45-10:05	Innovative liquid biomarkers in CNS lymphoma	Florian Scherer (Freiburg)
10:05-10:25	Spatial profiling of B cell malignancies	Scott Rodig (Boston)
10:25-10:45	Drug testing, functional therapeutic vulnerabilities, in lymphoid malignancies	Nathalie Javidi-Sharifi (Boston)
10:45-10:52	*<u>Selected brief oral communication</u>* *Clustering of peripheral immune profiles identifies distinct patient subgroups with differential clinical responses to epcoritamab in diffuse large B-cell lymphoma (DLBCL)*	*Daniele Bizzarri (Utrecht)*
10:52-10:55	*Discussion*	
10:55-11:25	*Panel discussion*	
11:25-11:35	***Closing Remarks***	

MEETING CLOSURE